Common metabolic features of hypertension and type 2 diabetes
- PMID: 36869145
- DOI: 10.1038/s41440-023-01233-x
Common metabolic features of hypertension and type 2 diabetes
Abstract
Hypertension and type 2 diabetes frequently coexist, suggesting that the two diseases have common pathophysiological bases. This review describes the pathophysiological mechanisms of how type 2 diabetes is frequently associated with hypertension. Multiple common factors mediate between both diseases. Factors that induce both type 2 diabetes and hypertension include obesity-induced hyperinsulinemia, activation of the sympathetic nervous system, chronic inflammation, and changes in adipokines. Vascular complications resulting from type 2 diabetes and hypertension include endothelial dysfunction, vasodilation/constriction dysfunction of peripheral vessels and increased peripheral vascular resistance, arteriosclerosis, and chronic kidney disease. While many of these vascular complications are caused by hypertension, they also exacerbate the pathology of hypertension. In addition, insulin resistance in the vasculature blunts insulin-induced vasodilation and blood flow to skeletal muscle, which contributes to impaired glucose uptake to skeletal muscle and glucose intolerance. In obese and insulin-resistant patients, increase in the circulating fluid volume forms the major pathophysiology of elevated blood pressure. On the other hand, in non-obese and/or insulin-deficient patients, especially those in the middle- or later stages of diabetes, peripheral vascular resistance is the major pathophysiology of hypertension. The relationship between various factors involved in the pathogenesis of type 2 diabetes and hypertension. It should be noted that all the factors shown in the figure are not necessarily present simultaneously in every patient.
Keywords: Hypertension; Insulin resistance; Obesity; Sympathetic nerve; Type 2 diabetes.
© 2023. The Author(s), under exclusive licence to The Japanese Society of Hypertension.
Similar articles
-
Insulin resistance and hyperinsulinemia in hypertension.J Hypertens Suppl. 1995 Aug;13(2):S65-72. doi: 10.1097/00004872-199508001-00010. J Hypertens Suppl. 1995. PMID: 8576790 Review.
-
Hyperinsulinemia, insulin resistance, and hypertension.J Cardiovasc Pharmacol. 1994;24 Suppl 2:S39-49. J Cardiovasc Pharmacol. 1994. PMID: 7898093 Review.
-
Cardiovascular and renal complications of type 2 diabetes in obesity: role of sympathetic nerve activity and insulin resistance.Curr Diabetes Rev. 2010 Mar;6(2):58-67. doi: 10.2174/157339910790909396. Curr Diabetes Rev. 2010. PMID: 20034369 Review.
-
Insulin as a vascular hormone: implications for the pathophysiology of cardiovascular disease.Clin Exp Pharmacol Physiol. 1998 Mar-Apr;25(3-4):175-84. doi: 10.1111/j.1440-1681.1998.t01-15-.x. Clin Exp Pharmacol Physiol. 1998. PMID: 9590566 Review.
-
Insulin resistance, hyperinsulinemia and hypertension.J Hypertens Suppl. 1993 Dec;11(5):S27-38. J Hypertens Suppl. 1993. PMID: 8158379 Review.
Cited by
-
Dose-response association of Chinese visceral adiposity index with comorbidity of hypertension and diabetes mellitus among elderly people.Front Endocrinol (Lausanne). 2023 May 12;14:1187381. doi: 10.3389/fendo.2023.1187381. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37251669 Free PMC article.
-
Investigating Ayurvedic Strategies: An In-Depth Examination of Managing Diabetes across Different Types.Curr Diabetes Rev. 2025;21(4):79-93. doi: 10.2174/0115733998284193240227041720. Curr Diabetes Rev. 2025. PMID: 38468519 Review.
-
Correlations Between Novel Adiposity Indices and Electrocardiographic Evidence of Left Ventricular Hypertrophy in Individuals with Arterial Hypertension.J Pers Med. 2025 Jun 2;15(6):229. doi: 10.3390/jpm15060229. J Pers Med. 2025. PMID: 40559092 Free PMC article.
-
Obesity and hypertension: Obesity medicine association (OMA) clinical practice statement (CPS) 2023.Obes Pillars. 2023 Aug 7;8:100083. doi: 10.1016/j.obpill.2023.100083. eCollection 2023 Dec. Obes Pillars. 2023. PMID: 38125655 Free PMC article.
-
Peroxisome proliferator-activated receptors, farnesoid X receptor, and dual modulating drugs in hypertension.Front Physiol. 2023 Jun 23;14:1186477. doi: 10.3389/fphys.2023.1186477. eCollection 2023. Front Physiol. 2023. PMID: 37427406 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical